Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Molecular determinants of drug binding and action on L-type calcium channels

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs

Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel

Binding Mechanisms Of 1,4-Dihydropyridine Derivatives To L-Type Calcium Channel Ca(V)1.2: A Molecular Modeling Study

Seeking the Exclusive Binding Region of Phenylalkylamine Derivatives on Human T‐type Calcium Channels Via Homology Modeling and Molecular Dynamics Simulation Approach

Structure, gating, and pharmacology of human Ca V 3.3 channel

L-type calcium channel antagonism - Translation from in vitro to in vivo

Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors

Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling

Physicochemical Basis for Binding and Voltage‐Dependent Block of Herg Channels by Structurally Diverse Drugs

Homology Modeling Identifies C-Terminal Residues That Contribute to the Ca2+ Sensitivity of A Bkca Channel

Phenylalkylamines in calcium channels: computational analysis of experimental structures

Ca2+-dependent modulation of voltage-gated myocyte sodium channels

Structural basis for human Ca v 3.2 inhibition by selective antagonists

Molecular determinants of state-dependent block of Na+ channels by local anesthetics.

Design of a functional calcium channel protein: inferences about an ion channel-forming motif derived from the primary structure of voltage-gated calcium channels

Targeting of Protein Phosphatases Pp2a and Pp2b to the C Terminus of L-Type Calcium Channel Ca(V)1.2

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Modulation of the Effects of Class-Ib Antiarrhythmics on Cardiac NaV1.5-encoded Channels by Accessory NaVβ Subunits

Antagonism of 4-Substituted 1,4-Dihydropyridine-3,5-dicarboxylates Toward Voltage-Dependent L-type Ca2+ Channels Ca V 1.3 and Ca V 1.2.

Regulation and drug modulation of a voltage-gated sodium channel: Pivotal role of the S4–S5 linker in activation and slow inactivation